It has been confirmed that TRIM16 overexpression inhibits epithelial-to-mesenchymal transition (EMT) process and the invasion of tumor cells in prostate carcinoma and also in non-small cell lung cancer (NSCLC) cells (Huo et al., 2015; Qi et al., 2016). Here, TRIM16 is linked to neoplasm.